First Time Loading...

Acorda Therapeutics Inc
NASDAQ:ACOR

Watchlist Manager
Acorda Therapeutics Inc Logo
Acorda Therapeutics Inc
NASDAQ:ACOR
Watchlist
Price: 0.879 USD 25.57% Market Closed
Updated: May 8, 2024
Section:
 

Relative Value

The Relative Value of one ACOR stock under the Base Case scenario is 179.312 USD. Compared to the current market price of 0.879 USD, Acorda Therapeutics Inc is Undervalued by 100%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ACOR Relative Value
Base Case
179.312 USD
Undervaluation 100%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

0
P/S
P/S
Price to Sales
0
vs History
96
vs Industry
97
Median 3Y
0.2
Median 5Y
0.2
Industry
8.3
Forward
0
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-0.3
Median 5Y
-0.3
Industry
26.8
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-1
Median 5Y
-0.8
Industry
23.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-0.5
Median 5Y
-0.5
Industry
21.4
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
80
Median 3Y
0.2
Median 5Y
0.2
Industry
2.6
More Details
Negative
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
76
Median 3Y
1.3
Median 5Y
1.2
Industry
7.5
Forward
-0.2
More Details
Negative
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
75
Median 3Y
1.7
Median 5Y
1.6
Industry
9.2
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
13
Median 3Y
-4.1
Median 5Y
-1.6
Industry
4.5
More Details
2.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
2.1
vs History
20
vs Industry
12
Median 3Y
-2.4
Median 5Y
-2.4
Industry
4.4
More Details
2.1
EV/OCF
EV/OCF
Enterprise Value to OCF
2.1
vs History
6
vs Industry
14
Median 3Y
-5.1
Median 5Y
-3.9
Industry
5.6
More Details
2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
2
vs History
1
vs Industry
11
Median 3Y
-5.1
Median 5Y
-3.9
Industry
3.4
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
68
Median 3Y
0.4
Median 5Y
0.4
Industry
5
More Details

Multiples Across Competitors

ACOR Competitors Multiples
Acorda Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Acorda Therapeutics Inc
NASDAQ:ACOR
1.1m USD 0 -0 -1.6 2.1
US
Abbvie Inc
NYSE:ABBV
282.8B USD 5.2 58.7 12.8 19.5
US
Amgen Inc
NASDAQ:AMGN
163.1B USD 5.5 43.4 18.4 30.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
108.8B USD 11 30 24.2 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
105.5B USD 8.1 27.3 22.1 24.5
AU
CSL Ltd
ASX:CSL
135.1B AUD 6.3 36 21.8 27
US
Gilead Sciences Inc
NASDAQ:GILD
81B USD 3 167.4 6.7 8.8
US
Moderna Inc
NASDAQ:MRNA
46.5B USD 9 -7.8 -8.5 -7.5
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Biogen Inc
NASDAQ:BIIB
32.1B USD 3.3 27.5 14.1 17.6
KR
Celltrion Inc
KRX:068270
40.3T KRW 18.5 75.3 46 63.4
EV/EBITDA Multiple
EBITDA Growth
US
Acorda Therapeutics Inc
NASDAQ:ACOR
Average EV/EBITDA: 20.7
Negative Multiple: -1.6 		N/A
US
Abbvie Inc
NYSE:ABBV
12.8
26%
US
Amgen Inc
NASDAQ:AMGN
18.4
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
59%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
22.1
50%
AU
CSL Ltd
ASX:CSL
21.8
54%
US
Gilead Sciences Inc
NASDAQ:GILD
6.7
18%
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -8.5 N/A
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -61.9 N/A
US
Biogen Inc
NASDAQ:BIIB
14.1
67%
KR
Celltrion Inc
KRX:068270
46
109%

See Also

Summary
ACOR intrinsic value, competitors valuation, and company profile.
DCF Valuation
ACOR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ACOR stock valuation using valuation multiples.
Wall Street Estimates
ACOR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ACOR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 135,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.